Editas Medicine Inc (NAS:EDIT)
$ 5.11 0.07 (1.39%) Market Cap: 420.24 Mil Enterprise Value: 158.20 Mil PE Ratio: 0 PB Ratio: 1.43 GF Score: 52/100

Q3 2019 Editas Medicine Inc Earnings Call Transcript

Nov 12, 2019 / 01:00PM GMT
Release Date Price: $22.32 (+9.47%)
Operator

Good morning, and welcome to Editas Medicine's Third Quarter 2019 Conference Call.

(Operator Instructions) Please be advised that this call is being recorded at the company's request.

I would now like to turn the call over to Mark Mullikin, Vice President of Finance and Investor Relations at Editas Medicine.

Mark J. Mullikin
Editas Medicine, Inc. - Senior Director of Finance & IR

Thank you, operator. Good morning, everyone, and welcome to our third quarter 2019 conference call. Earlier this morning, we issued 2 press releases that will be discussed on this call. The first announces an amendment to our long-standing collaboration with Celgene. The second press release provides our financial results and corporate updates for the third quarter of 2019.

A replay of today's call will be available on the Investors and Media section of our website approximately 2 hours after its completion. After our prepared remarks, we will open the call for Q&A.

As a reminder, various remarks that we make during this call about the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot